NATCOPHARM.NSNATCOPHARM.NSNSE
Loading
Cash Flow Under PressureContracting
Percentile Rank93
3Y CAGR+16.2%
5Y CAGR+87.0%
Year-over-Year Change
Operating cash flow minus capital expenditures
3Y CAGR
+16.2%/yr
vs +32.8%/yr prior
5Y CAGR
+87.0%/yr
Recent deceleration
Acceleration
-16.5pp
Decelerating
Percentile
P93
Near historical high
vs 5Y Ago
22.9x
Strong expansion
Streak
1 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| TTM | $10.10B | -29.3% |
| 2025 | $14.28B | +63.7% |
| 2024 | $8.72B | +35.5% |
| 2023 | $6.43B | +428.0% |
| 2022 | $-1.96B | -543.9% |
| 2021 | $442.00M | -24.7% |
| 2020 | $587.00M | -71.7% |
| 2019 | $2.07B | +427.0% |
| 2018 | $393.00M | -40.7% |
| 2017 | $663.00M | - |